SinoMab Bioscience Ltd. is a clinical stage biopharmaceutical company, which engages in the research, development, and manufacture of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody-based biologics. The company was founded by Shui On Leung on April 27, 2001, and is headquartered in Hong Kong.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company